Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
954 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,459 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (494)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07158710 | Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation | recruiting | Phase 1 | 159 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05342883 | GammaTile and Stupp in Newly Diagnosed GBM(GESTALT) | active not recruiting | Phase 4 | 61 | GT Medical Technologies, Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06102525 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma | recruiting | Phase 1 / Phase 2 | 43 | Rznomics, Inc.OTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07111117 | Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.(NEUROBLASTOTEP) | not yet recruiting | Phase 2 | 30 | Institut CurieOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07141862 | Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method(PREFERPUBER) | recruiting | — | 89 | University Hospital, Clermont-FerrandOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT04863950 | Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma | recruiting | Phase 2 | 25 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07144735 | Allogeneic γδT Cells in Glioblastoma(ABOUT) | recruiting | N/A | 18 | Peking University Third HospitalOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04587830 | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme(GBM) | active not recruiting | Phase 2 | 100 | Polaris GroupINDUSTRY | 2 | Aug 26, 2025 | clinicaltrials |
| NCT07138001 | Phase 2 Clinical Trial of KH617 | not yet recruiting | Phase 2 | 60 | Sichuan Honghe Biotechnology Co., Ltd.INDUSTRY | 0 | Aug 22, 2025 | clinicaltrials |
| NCT04747145 | Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma | active not recruiting | Phase 2 | 38 | Medical College of WisconsinOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT04910022 | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 150 | Nerviano Medical SciencesINDUSTRY | 5 | Aug 19, 2025 | clinicaltrials |
| NCT06018363 | Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection | recruiting | Phase 1 / Phase 2 | 25 | Dushu Lake Hospital Affiliated to Soochow UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07130149 | Sonodynamic-Chemoradiotherapy Integration in Glioblastoma | enrolling by invitation | Phase 2 | 230 | Yingjuan ZhengOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05222802 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | active not recruiting | Phase 1 | 52 | Katmai Pharmaceuticals Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06385132 | Psychological and Psychiatric prOfile in Glioblastoma and Head and Neck Cancer(APPOINT) | recruiting | — | 207 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07121842 | Glioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI(GLIMPCE) | recruiting | N/A | 120 | Erasmus Medical CenterOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07119294 | Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study.(GlioFAPI) | recruiting | N/A | 50 | Jules Bordet InstituteOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT05135975 | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | recruiting | Phase 2 | 86 | Nationwide Children's HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03672721 | IA Carboplatin + Radiotherapy in Relapsing GBM | recruiting | Phase 1 / Phase 2 | 35 | Université de SherbrookeOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05970757 | Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma(PhysMRRT) | active not recruiting | N/A | 10 | Erasmus Medical CenterOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06617208 | Prognostic IntraOperative Biomarkers ideNtification in Tumor rElatEd suRgery(PIONEER) | not yet recruiting | N/A | 10 | Erasmus Medical CenterOTHER | 0 | Aug 8, 2025 | clinicaltrials |
| NCT06852807 | 18F-mFBG PET Imaging in the Evaluation of Neuroblastoma | recruiting | — | 200 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07111195 | Feasibility of ONCOhabitats for Surgical and Treatment Planning in IDH-Wildtype Glioblastoma (SINUE)(SINUE) | recruiting | — | 140 | Juan M Garcia-GomezOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT06356883 | Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma | recruiting | Phase 2 | 120 | Université de SherbrookeOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05947149 | HRQoL in Patients With Solid Tumors Treated With Hadrontherapy(HadroQoL) | recruiting | — | 180 | CNAO National Center of Oncological HadrontherapyOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07023640 | Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors | recruiting | N/A | 50 | Peking Union Medical College HospitalOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT04961515 | Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma | recruiting | Phase 2 | 19 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06430424 | Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma(GBrecurr) | recruiting | — | 40 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04175301 | Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas. | active not recruiting | Phase 2 | 15 | Stony Brook UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07067346 | Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma | recruiting | Early Phase 1 | 10 | Sichuan UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07090538 | GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma. | not yet recruiting | Early Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07092202 | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases | recruiting | Phase 4 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05929495 | Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma | recruiting | Phase 2 | 25 | University of Milano BicoccaOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04135807 | Implantable Microdevice In Primary Brain Tumors | recruiting | Early Phase 1 | 12 | Oliver JonasOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04523688 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma(Combi G-Vax) | recruiting | Phase 2 | 28 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05192980 | SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours(BIOPORTAL) | recruiting | N/A | 600 | Institut CurieOTHER | 4 | Jul 22, 2025 | clinicaltrials |
| NCT05909618 | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases(14) | recruiting | Phase 2 | 33 | Sheba Medical CenterOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07064746 | Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma(MIBG & SSTR NB) | recruiting | — | 150 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT07074470 | Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL(VPX) | recruiting | N/A | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06092125 | Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease(CAMIND) | recruiting | — | 2,300 | Xuanwu Hospital, BeijingOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06099743 | ASCENT Intervention for Brain Tumor Patients | recruiting | N/A | 100 | Massachusetts General HospitalOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT03893487 | Fimepinostat in Treating Brain Tumors in Children and Young Adults(PNOC016) | active not recruiting | Early Phase 1 | 30 | Sabine Mueller, MD, PhDOTHER | 2 | Jul 11, 2025 | clinicaltrials |
| NCT04266977 | Restrictive Use of Dexamethasone in Glioblastoma(RESDEX) | recruiting | N/A | 50 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06773481 | BC008-1A Injection for Recurrent CNS WHO G4 Glioma | recruiting | Phase 1 | 40 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06485947 | Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma(DBPilot) | recruiting | Phase 1 | 38 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07047066 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Tongji HospitalOTHER | 0 | Jul 2, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Sep 8, 2025source: clinicaltrials